Annals of Colorectal Research

Published by: Kowsar

Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease

Tsvetelina Veselinova Velikova 1 , * , Zoya Angelova Spassova 2 , Lyuben Mitkov Milatchkov 2 , Dobriana Georgieva Panova 2 , Ekaterina Ivanova Ivanova - Todorova 3 , Kalina Dinkova Tumangelova - Yuzeir 3 , Ekaterina Krasimirova Kurteva 3 , Dobroslav Stanimirov Kyurkchiev 3 , Siragan Arshavir Deredjan 2 , Rosen Kirilov Nikolov 2 , Iskra Petrova Altankova 1 and Lyudmila Mateva Vladimirova 2
Authors Information
1 Clinical Immunology, University Hospital Lozenetz, Sofia, Bulgaria
2 Clinic of Gastroenterology, University Hospital St. Ivan Rilski, Sofia, Bulgaria
3 Department of Clinical Laboratory and Clinical Immunology, University Hospital St. Ivan Rilski, Sofia, Bulgaria
Article information
  • Annals of Colorectal Research: March 2018, 6 (1); e68674
  • Published Online: March 31, 2018
  • Article Type: Research Article
  • Received: March 14, 2018
  • Accepted: March 22, 2018
  • DOI: 10.5812/acr.68674

To Cite: Velikova T V, Spassova Z A, Milatchkov L M, Panova D G, Ivanova - Todorova E I, et al. Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease, Ann Colorectal Res. 2018 ; 6(1):e68674. doi: 10.5812/acr.68674.

Copyright © 2018, Annals of Colorectal Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97(6):1458-62. doi: 10.1111/j.1572-0241.2002.05689.x. [PubMed: 12094865].
  • 2. Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, et al. Can We Predict the Efficacy of Anti-TNF-alpha Agents? Int J Mol Sci. 2017;18(9). doi: 10.3390/ijms18091973. [PubMed: 28906475]. [PubMed Central: PMC5618622].
  • 3. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8(1):23-36. doi: 10.1177/1756283X14553384. [PubMed: 25553077]. [PubMed Central: PMC4265086].
  • 4. Olbjorn C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414-9. doi: 10.1080/00365521.2016.1259653. [PubMed: 27887202].
  • 5. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-1826 e2. doi: 10.1053/j.gastro.2010.11.058. [PubMed: 21530748]. [PubMed Central: PMC3749298].
  • 6. Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-10. doi: 10.3748/wjg.v22.i3.1304. [PubMed: 26811667]. [PubMed Central: PMC4716040].
  • 7. Kyurkchiev D, Mladenova T, Panova D, Spassova Z, Altankova I. Antibodies against Saccharomyces cerevisiae (ASCA) in patients with Crohn's disease and ulcerative colitis. Bulgarian hepatogastroenterol. 2012;1:21-4.
  • 8. Velikova TV. Investigations of immunological parameters for intestinal inflammation in order to establish new markers for diagnosis and follow-up of inflammatory bowel disease. Sofia, Bulgaria: Medical University of Sofia; 2014.
  • 9. Mitev S, Petkova M, Velikova T, Ivanova-Todorova E, Shentova R, Yaneva P, et al. Prevalence of anti-saccharomyces cerevisiae antibodies in bulgarian patients with crohn’s disease. Comptes rendus de l’Académie bulgare des Sciences. 2017;70(2). doi: 10.13140/RG.2.2.36494.87366.
  • 10. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5(1):61-3. discussion 66-7. [PubMed: 10028450].
  • 11. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4(1):7-27. doi: 10.1016/j.crohns.2009.12.003. [PubMed: 21122488].
  • 12. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30-51. doi: 10.1111/apt.13445. [PubMed: 26515897].
  • 13. Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol. 2012;18(46):6782-9. doi: 10.3748/wjg.v18.i46.6782. [PubMed: 23239916]. [PubMed Central: PMC3520167].
  • 14. Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol. 2010;45(3):325-31. doi: 10.3109/00365520903483650. [PubMed: 20034360].
  • 15. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14(10):1392-8. doi: 10.1002/ibd.20490. [PubMed: 18484671].
  • 16. Molander P, af Bjorkesten CG, Mustonen H, Haapamaki J, Vauhkonen M, Kolho KL, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis. 2012;18(11):2011-7. doi: 10.1002/ibd.22863. [PubMed: 22223566].
  • 17. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104(3):760-7. doi: 10.1038/ajg.2008.88. [PubMed: 19174781].
  • 18. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22. [PubMed: 10889150].
  • 19. Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340-5. doi: 10.1097/MEG.0b013e32832bab49. [PubMed: 19581809].
  • 20. Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34(4):462-9. doi: 10.1111/j.1365-2036.2011.04743.x. [PubMed: 21671970].
  • 21. Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22(3):1017-33. doi: 10.3748/wjg.v22.i3.1017. [PubMed: 26811644]. [PubMed Central: PMC4716017].
  • 22. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17(12):1451-7. [PubMed: 12823146].
  • 23. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125(1):32-9. [PubMed: 12851868].
  • 24. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005;1051:559-69. doi: 10.1196/annals.1361.100. [PubMed: 16126996].
  • 25. Katsanos KH, Voulgari PV, Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis. 2012;6(7):735-42. doi: 10.1016/j.crohns.2012.03.005. [PubMed: 22504032].
  • 26. Michalopoulos G, Vrakas S, Makris K, Tzathas C. Systemic lupus erythematosus in Crohn's disease: drug-induced or idiopathic? Ann Gastroenterol. 2015;28(3):408-9. [PubMed: 26126856]. [PubMed Central: PMC4460384].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments